IN2014CN04187A - - Google Patents

Info

Publication number
IN2014CN04187A
IN2014CN04187A IN4187CHN2014A IN2014CN04187A IN 2014CN04187 A IN2014CN04187 A IN 2014CN04187A IN 4187CHN2014 A IN4187CHN2014 A IN 4187CHN2014A IN 2014CN04187 A IN2014CN04187 A IN 2014CN04187A
Authority
IN
India
Prior art keywords
toxin
recombinant
cdta
toxins
relates
Prior art date
Application number
Other languages
English (en)
Inventor
Jon Henry Heinrichs
Jean Luc Bodmer
Susan Lynn Secore
Aaron Rudy Goerke
Aguilar Ivette Caro
Marie Pierre Gentile
Melanie S Horton
Matthew Ryan Miezeiewski
Julie M Skinner
Paulus Jacobus Antonius Sondermeijer
Shyamsundar Subramanian
Liefkens Karin Huberdina Antonia Van Der Heijden
Su Wang
Jinfu Xie
Rachel Flora Xoconostle
Julie K Zorman
Original Assignee
Merck Sharp & Dohme
Intervet Int Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme, Intervet Int Bv filed Critical Merck Sharp & Dohme
Publication of IN2014CN04187A publication Critical patent/IN2014CN04187A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1077—Pentosyltransferases (2.4.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN4187CHN2014 2012-01-27 2013-01-25 IN2014CN04187A (xx)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261591631P 2012-01-27 2012-01-27
US201261596419P 2012-02-08 2012-02-08
US201261703754P 2012-09-20 2012-09-20
PCT/US2013/023189 WO2013112867A1 (en) 2012-01-27 2013-01-25 Vaccines against clostridium difficile comprising recombinant toxins

Publications (1)

Publication Number Publication Date
IN2014CN04187A true IN2014CN04187A (xx) 2015-07-17

Family

ID=48873956

Family Applications (1)

Application Number Title Priority Date Filing Date
IN4187CHN2014 IN2014CN04187A (xx) 2012-01-27 2013-01-25

Country Status (14)

Country Link
US (1) US9388394B2 (xx)
EP (1) EP2807186A4 (xx)
JP (2) JP2015506948A (xx)
KR (1) KR20140117433A (xx)
CN (1) CN104039816B (xx)
AR (1) AR089797A1 (xx)
AU (1) AU2013211973B2 (xx)
BR (1) BR112014018432A8 (xx)
CA (1) CA2856443A1 (xx)
IN (1) IN2014CN04187A (xx)
MX (1) MX351074B (xx)
RU (1) RU2014134365A (xx)
TW (1) TW201335178A (xx)
WO (1) WO2013112867A1 (xx)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201602668VA (en) * 2011-04-22 2016-05-30 Wyeth Llc Compositions relating to a mutant clostridium difficile toxin and methods thereof
SG11201402375VA (en) * 2011-12-08 2014-10-30 Novartis Ag Clostridium difficile toxin-based vaccine
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
GB201223342D0 (en) * 2012-12-23 2013-02-06 Glaxosmithkline Biolog Sa Immunogenic composition
AU2014257172B2 (en) * 2013-04-22 2019-01-31 Board Of Regents Of The University Of Oklahoma Clostridium difficile vaccine and methods of use
WO2014197651A1 (en) * 2013-06-05 2014-12-11 Tufts University Atoxic recombinant holotoxins of clostridium difficile as immunogens
AU2014277981B2 (en) 2013-06-14 2019-06-20 Sanofi Pasteur Inc. Compositions and methods of immunizing against C. difficile
SI3160500T1 (sl) * 2014-06-25 2019-11-29 Glaxosmithkline Biologicals Sa Imunogeni sestavek proti Clostridium difficile
JP2017212882A (ja) * 2014-10-10 2017-12-07 学校法人 名城大学 アセチルエステラーゼ及びその利用
US20180110849A1 (en) 2015-05-15 2018-04-26 Sanofi Pasteur, Inc. Methods for immunizing against clostridium difficile
TW201718627A (zh) 2015-06-11 2017-06-01 梅茲製藥有限兩合公司 重組梭菌神經毒素及其使用與形成方法、包括其之醫藥組合物及對應其之前驅物、編碼前驅物之核酸序列及其獲得方法與前驅物之形成方法、載體與包括核酸序列之重組宿主細胞
CA3010146A1 (en) 2016-03-02 2017-09-08 Merz Pharma Gmbh & Co. Kgaa Composition comprising botulinum toxin
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
BR112019012203A2 (pt) * 2016-12-14 2019-11-12 Beijing Genomics Inst At Shenzhen marcadores genéticos humanos associados à resposta para tratamentos que têm como alvo a toxina b de clostridium difficile
US10668140B2 (en) 2017-02-24 2020-06-02 University Of South Floirida Non-toxigenic Clostridium difficile spores for use in oral vaccination
CA3056090A1 (en) 2017-03-15 2018-09-20 Novavax, Inc. Methods and compositions for inducing immune responses against clostridium difficile
US10555992B2 (en) 2017-05-31 2020-02-11 University Of South Florida Immunogenic proteins against clostridium difficile
EP3634480A1 (en) * 2017-06-09 2020-04-15 Hipra Scientific, S.L.U. Vaccine comprising clostridium toxoids
US11952601B2 (en) 2017-06-20 2024-04-09 Merz Pharma Gmbh & Co. Kgaa Recombinant botulinum toxin with increased duration of effect
EP3649143B1 (en) 2017-07-06 2022-08-31 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum neurotoxins with increased duration of effect
US10933126B2 (en) 2018-05-03 2021-03-02 The Board Of Regents Of The University Of Oklahoma Clostridium difficile immunogenic compositions and methods of use
WO2020078420A1 (en) * 2018-10-17 2020-04-23 Eternity Biomedical Laboratories, Inc. Immunogenic preparations and methods against clostridium difficile infection
CN110041437B (zh) * 2019-04-29 2020-12-25 中国兽医药品监察所 一种无毒性破伤风毒素和诺维梭菌α毒素重组融合蛋白
CN110607314B (zh) * 2019-10-31 2022-09-23 四川农业大学 一种TcdB RBD基因、重组RBD蛋白和应用
CN112442472B (zh) * 2020-11-30 2023-05-26 四川大学华西医院 抗艰难梭菌的重组乳酸乳球菌、活载体疫苗及其制备方法
WO2023143559A1 (en) * 2022-01-30 2023-08-03 Westlake University Tfpi binding polypeptides and uses thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919665A (en) 1989-10-31 1999-07-06 Ophidian Pharmaceuticals, Inc. Vaccine for clostridium botulinum neurotoxin
WO1998059053A1 (en) 1997-06-20 1998-12-30 Queen Mary & Westfield College Immonogenic fragments of toxin a of clostridium difficile
US6969520B2 (en) 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
DE69829400T2 (de) 1997-10-20 2006-04-13 Acambis, Inc., Cambridge Passive immunisierung gegen durch clostridium difficile verursachte krankheit
WO2000061761A2 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
US7226597B2 (en) 2002-06-17 2007-06-05 The Board Of Regents Of The University Of Oklahoma Mutants of Clostridium difficile toxin B and methods of use
AU2004304770B2 (en) 2003-12-08 2010-05-06 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory properties by small oligonucleotide-based compounds
CA2553946C (en) 2004-02-06 2019-02-26 University Of Massachusetts Antibodies against clostridium difficile toxins and uses thereof
US7470674B2 (en) 2005-11-07 2008-12-30 Idera Pharmaceuticals, Inc. Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
PL2004220T3 (pl) * 2006-03-30 2015-11-30 Zoetis Services Llc Sposoby i kompozycje do szczepienia drobiu
NO2396652T3 (xx) 2009-02-11 2018-05-12
US8709428B2 (en) * 2009-02-20 2014-04-29 Health Protection Agency Antibodies to Clostridium difficile toxins
EP2470664A4 (en) * 2009-08-27 2013-01-16 Synaptic Res Llc NEW PROTEIN RELEASE SYSTEM FOR GENERATING INDUCED PLURIPOTENTAL STEM CELLS OR TISSUE-SPECIFIC CELLS
US10046040B2 (en) 2009-11-16 2018-08-14 University Of Maryland, Baltimore Multivalent live vector vaccine against Clostridium difficile-associated disease
CA2782406A1 (en) 2009-12-02 2011-06-09 Tufts University Atoxic recombinant holotoxins of clostridium difficile as immunogens
GB0921288D0 (en) * 2009-12-04 2010-01-20 Health Prot Agency Therapies for preventing or suppressing clostridium difficile infection
US9598472B2 (en) 2010-09-03 2017-03-21 Valneva Austria Gmbh Isolated polypeptide of the toxin A and toxin B proteins of C. difficile and uses thereof
US8431361B2 (en) * 2010-09-17 2013-04-30 Board Of Regents Of The University Of Oklahoma Bacterial cells, optimized nucleotide sequences and methods for improved expression of recombinant Clostridium difficile toxin B
SG10201602668VA (en) * 2011-04-22 2016-05-30 Wyeth Llc Compositions relating to a mutant clostridium difficile toxin and methods thereof

Also Published As

Publication number Publication date
CN104039816A (zh) 2014-09-10
AU2013211973B2 (en) 2017-10-12
KR20140117433A (ko) 2014-10-07
WO2013112867A1 (en) 2013-08-01
BR112014018432A8 (pt) 2017-07-11
CA2856443A1 (en) 2013-08-01
US9388394B2 (en) 2016-07-12
AU2013211973A1 (en) 2014-06-12
JP2017141226A (ja) 2017-08-17
US20150044250A1 (en) 2015-02-12
MX351074B (es) 2017-09-28
TW201335178A (zh) 2013-09-01
CN104039816B (zh) 2018-02-09
EP2807186A1 (en) 2014-12-03
MX2014009106A (es) 2014-11-10
EP2807186A4 (en) 2016-01-27
AR089797A1 (es) 2014-09-17
RU2014134365A (ru) 2016-03-20
JP2015506948A (ja) 2015-03-05
BR112014018432A2 (xx) 2017-06-20

Similar Documents

Publication Publication Date Title
IN2014CN04187A (xx)
BR112016024352A2 (pt) ?cepa de listeria recombinante, listeria recombinante, composição farmacêutica, e, métodos de induzir uma resposta imune contra um tumor ou um câncer em um indivíduo humano e de listeria?
EP4272750A3 (en) Protein antigens that provide protection against pneumococcal colonization and/or disease
WO2018144093A3 (en) ENHANCED SKIN CARE FORMULATIONS
EP3616716A3 (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
MX2018004598A (es) Cepas vacunales recombinantes de listeria y métodos para usar las mismas en la inmunoterapia contra el cáncer.
SG10201903349YA (en) Recombinant listeria vaccine strains and methods of using the same in cancer immunotherapy
WO2017214596A8 (en) Compositions and methods for preventing and treating zika virus infection
MX2014010417A (es) Formulaciones adyuvadas de vacunas de difteria, tetanos y tos ferina (dtp) de refuerzo.
PH12015501716B1 (en) Anti-mycoplasma spp. subunit vaccine
EA201590829A1 (ru) Новые мукозные адъюванты и системы доставки
WO2017142843A8 (en) Novel antigen for use in malaria vaccine
MX2020008454A (es) Composicion inmunogenica que comprende antigenos estafilococicos.
WO2015051371A3 (en) Haemophilus parasuis vaccine serovar type four
EP4241851A3 (en) Immunogenic compositions
MX2021007502A (es) Formulaciones y métodos de vacuna de norovirus.
MX2016000107A (es) Osteopontina lactea de mamifero para mejorar la capacidad de respuesta inmunitaria.
MX2015017257A (es) Composiciones y metodos de inmunizar contra clostridium difficile.
WO2019099578A8 (en) Use of imidazopyrimidine for modulating human immune response
NZ704188A (en) Attenuated swine influenza vaccines and methods of making and use thereof
WO2013084070A3 (en) Salmonella vaccine proteins
MX2016002823A (es) Metodos y composiciones para vacunas vectorizadas virales.
MX2017014666A (es) Metodos de inmunización contra clostridium difficile.
MX357431B (es) Vacuna contra garrapatas rhipicephalus.
CL2014001126A1 (es) Composición farmacéutica útil como vacuna contra bacterias escherichia coli productoras de shigatoxinas (stec), que comprende al menos un antígeno o una proteína de membrana externa inmunogénica o proteína inmunogénica asociada y conservada en cepas stec.